AstraZeneca to launch direct-to-patient medication platform

WILMINGTON - AstraZeneca (AZN), a prominent pharmaceutical company with a market capitalization of $228 billion and an impressive 82% gross profit margin, announced Thursday the upcoming launch of AstraZeneca Direct, an online platform that will allow eligible patients to purchase prescribed medications at reduced cash prices with home delivery. According to InvestingPro data, the company’s strong financial health and 15% revenue growth demonstrate its robust position to expand direct-to-consumer services.

Starting October 1, patients with prescriptions for AIRSUPRA (albuterol/budesonide) or FARXIGA (dapaglifozin) can purchase these medications directly through the platform at prices up to 70% off list price. The company will also offer FLUMIST (Influenza Vaccine Live, Intranasal) for home delivery through the service. Want deeper insights into AstraZeneca’s financial health and growth potential? Access the comprehensive Pro Research Report, available exclusively on InvestingPro.

"We remain deeply committed to improving accessibility, affordability, and driving innovation in healthcare," said Joris Silon, US Country President at AstraZeneca, according to the press release.

The new service will complement AstraZeneca’s existing patient support programs, which will continue unchanged. These programs help eligible patients access prescribed AstraZeneca medications at no or reduced cost.

FLUMIST home delivery will initially be available in 34 states for the 2025-2026 flu season, with plans to expand to all 48 contiguous states in future seasons. The FDA approved FLUMIST for self-administration in September 2024 after studies showed that individuals over 18 years of age could safely administer the nasal spray vaccine.

AstraZeneca Direct represents the company’s effort to provide patients with chronic conditions such as asthma, diabetes, heart failure, and chronic kidney disease with a more convenient way to access their medications.

The online platform will be accessible at AstraZenecaDirect.com starting Wednesday, October 1, 2025. Based on InvestingPro’s Fair Value analysis, AstraZeneca currently appears undervalued, suggesting potential upside for investors as the company continues to innovate in healthcare delivery and maintain its 33-year track record of consistent dividend payments.

In other recent news, AstraZeneca has reported positive outcomes from its Phase III TULIP-SC trial for Saphnelo (anifrolumab), showing a statistically significant reduction in disease activity for patients with systemic lupus erythematosus. The trial results indicate that the subcutaneous administration of Saphnelo is effective and maintains a safety profile consistent with its intravenous counterpart. Additionally, AstraZeneca received a recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use for Koselugo (selumetinib) to treat adults with neurofibromatosis type 1. This recommendation is based on the KOMET Phase III trial, which demonstrated a notable response rate in patients treated with Koselugo.

Furthermore, AstraZeneca has expanded its collaboration with SOPHiA GENETICS to enhance cancer detection technologies, specifically targeting genetic mutations related to breast and prostate cancer. This collaboration aims to optimize next-generation sequencing solutions for better identification of mutations in the PIK3CA/AKT1/PTEN pathway. In other developments, AstraZeneca’s Non-Executive Director Karen Knudsen acquired 9 American Depositary Shares through dividend reinvestment, highlighting continued insider confidence in the company. These recent developments underscore AstraZeneca’s ongoing efforts in advancing its research and development initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.